Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience
Year: 2024
Type: article
Study design: Observational Study
Abstract: Combination antifungal therapy for invasive mucormycosis remains controversial and is inconsistently defined in prior studies. In a cohort of patients with immunocompromised status and invasive mucormycosis, we found no difference in 6-week mortality with up-front or salvage combination therapy as compared with monotherapy.
Source: Open Forum Infectious Diseases
DOI: 10.1093/ofid/ofae103
Authors: Brian Lu, David Ha, Sa Shen, Jessica Ferguson Toll, Ailin Kim, Sarah Kim, Emily Mui, Stan Deresinski, Marisa Holubar, William Alegria
Institutions: Stanford Health Care, Stanford University, Stanford Medicine
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,256
OpenAlex ID: W4392058810